Hawthorn Blood Pressure Meta-analysis: What the Evidence Says

Quick Answer

Hawthorn Blood Pressure Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Despite the availability of many therapeutic options to reduce blood pressure, it is estimated that therapy for four out of five hypertensive patients is inadequate, mainly due to reduced adherence and poor compliance. [Szikora Zsóka (2025); evidence level 1]
• A recently published systematic review found that hawthorn can reduce blood pressure; however, the results of the individual trials included in this review were not statistically analyzed. [Szikora Zsóka (2025); evidence level 1]
• Eating properly selected foods can not only support daily bodily functions but also reduce the risk of free radical-related diseases, which are largely related to oxidative stress. [Kępińska-Pacelik Jagoda (2026); evidence level 4]
• Hawthorn berries are rich in polyphenols, flavonoids, and other compounds with antioxidant properties, making them an attractive raw material for the development of functional food products that support the elimination of reactive oxygen species and reduce the risk of free radical-related diseases. [Kępińska-Pacelik Jagoda (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For hawthorn blood pressure meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Szikora Zsóka (2025). Hawthorn ( Crataegus  spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials. DOI: 10.3390/ph18071027. PMCID: PMC12298042. PMID: 40732315. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12298042/
• Kępińska-Pacelik Jagoda (2026). Hawthorn ( Crataegus monogyna Jacq.): A Review of Therapeutic Potential and Applications. DOI: 10.3390/molecules31020226. PMCID: PMC12844126. PMID: 41599280. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12844126/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.